Cefamandole (sodium)

Cefamandole (Cephamandole) sodium is a semi-synthetic second-generation cephalosporin antibiotic with broad-spectrum antimicrobial activity. Cefamandole sodium is resistant to hydrolysis by β-lactamases produced by some Gram-negative bacteria. Cefamandole sodium kills Gram-positive cocci and various Gram-negative bacilli mainly by inhibiting cell wall synthesis, but it is inactive against Pseudomonas, Proteus vulgaris and Providencia stuartii, and its efficacy is affected by inoculum size. The plasma elimination half-life of Cefamandole sodium in rats is only 0.4 h, it is mainly excreted in urine in biologically active form, and it hardly penetrates the non-inflamed blood-brain barrier. Cefamandole sodium is widely used in studies related to bacterial infections^[1][2][3]. In Vitro:Cefamandole (sodium) (30 μg/mL; 0, 1, 3, 6, 12 h) is hydrolyzed by beta-lactamases from Enterobacter cloacae, Serratia marcescens, and Proteus morganii, allowing bacterial growth to resume after hydrolysis is complete, while Pseudomonas aeruginosa grows despite cefamandole presence prior to hydrolysis^[1].
Cefamandole (sodium) (0.12-64 μg/mL; 18 h) inhibits 90-100% of methicillin-susceptible S. aureus, group A and B streptococci, S. pneumoniae, N. gonorrhoeae, H. influenzae, and S. typhosa^[3]. In Vivo:Following subcutaneous administration of a single dose of cefamandole sodium (100 mg/kg) to male Long-Evans rats, a peak plasma concentration of 49 μg/mL is reached at 0.5 h, with a plasma half-life of 0.4 h^[4].
Cefamandole sodium (50 mg/kg; intravenous administration; single dose) exhibits free drug pharmacokinetic characteristics consistent with a two-compartment model in male Sprague-Dawley rats, with an elimination half-life of 21.6 min^[5].